Literature DB >> 8568300

Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly.

U Sankilampi1, P O Honkanen, A Bloigu, E Herva, M Leinonen.   

Abstract

Antibody response to 23-valent pneumococcal vaccine was assessed in 350 subjects (131 men, 219 women) aged 65-91 years. IgG antibodies to pneumococcal serotypes 4, 6B, 9V, 14, 19F, and 23F were measured by EIA after blocking of antibodies to cell wall polysaccharide. Antibody concentrations in both pre- and postvaccination sera (mean interval, 35 days) were higher in elderly men than women; in the women, the concentrations decreased significantly with increasing age, but not in the men. Antibody fold increases were good in the elderly, including those > or = 85 years old. The overall percentage of the elderly with antibody concentrations > 1 microgram/mL to the 6 antigens increased by vaccination from 61% to 87%, but in the women > or = 85 years old, only to 75%. Antibody response to 23-valent pneumococcal vaccine was satisfactory in the elderly.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568300     DOI: 10.1093/infdis/173.2.387

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

Review 1.  Sex and Gender Impact Immune Responses to Vaccines Among the Elderly.

Authors:  Ashley L Fink; Sabra L Klein
Journal:  Physiology (Bethesda)       Date:  2015-11

2.  Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination.

Authors:  Meng Chen; Yuki Hisatomi; Akitsugu Furumoto; Kenji Kawakami; Hironori Masaki; Tsuyoshi Nagatake; Yoshiko Sueyasu; Tomoaki Iwanaga; Hisamichi Aizawa; Kazunori Oishi
Journal:  Clin Vaccine Immunol       Date:  2006-12-13

Review 3.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

4.  Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination.

Authors:  J B Rubins; M Alter; J Loch; E N Janoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

5.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

Review 6.  Pneumococcal disease in the elderly: what is preventing vaccine efficacy?

Authors:  J B Rubins; E N Janoff
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  The effect of age on the response to the pneumococcal polysaccharide vaccine.

Authors:  Hyunju Lee; Moon H Nahm; Kyung-Hyo Kim
Journal:  BMC Infect Dis       Date:  2010-03-10       Impact factor: 3.090

Review 8.  Advances in pneumococcal vaccines: what are the advantages for the elderly?

Authors:  Angel Vila-Córcoles
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins.

Authors:  Birgit Simell; Mika Lahdenkari; Antti Reunanen; Helena Käyhty; Merja Väkeväinen
Journal:  Clin Vaccine Immunol       Date:  2008-07-02

Review 10.  Pneumococcal vaccination and revaccination of older adults.

Authors:  Andrew S Artz; William B Ershler; Dan L Longo
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.